TABLE 1.

Recipient Requirements by Selection of Clinical Trials

Clinical Trial and Location	Year Clinical Trial Established	Minimum Number of Cryopreserved Embryos	PGT-A Required	Renal Pathology Excluded	Age
Baylor University Medical Center Dallas, Texas	November 2015	At least 2 d 5–6 euploid blastocysts of satisfactory quality, increased to 4 good-quality euploid blastocysts midway through study	Yes	Exclude individuals with renal malformations (not including single kidney)	20-35 at the time of IVF
Cleveland Clinic Cleveland, Ohio	October 2015	6	No	Exclude individuals with presence of low-lying pelvic kidney(s)	21-45 (embryos produced between age 21-39)
Institute for Clinical and Experimental Medicine Prague, Czechia	October 2015	10	No	Not specified	18-40
Hammersmith Hospital, Imperial College NHS Trust London, UK	February 2019	≥ 10 embryos	Not specified	Exclude individuals with renal pathology	24-38 (or 40 if eggs frozen <38)
University of Pennsylvania, Philadelphia, Pennsylvania	November 2017	≥ 2 high quality blastocysts	No	Exclude individuals with renal abnormalities (including single kidney or pelvic kidneys)	21-40

IVF indicates in vitro fertilization; PGT-A, preimplantation genetic testing for aneuploidy.